[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"infection-in-an-immunocompromised-host\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:infection-in-an-immunocompromised-host":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100249954","phase-2-third-party-viral-specific-t-cells-vsts-100249954",false,"NCT02532452","Third Party Viral Specific T-cells (VSTs)","Third Party Viral Specific T-cells (VSTs) for Treatment of Viral Infections in Immunocompromised Patients","Inclusion Criteria:\n\n* Immunocompromised patient with evidence of viral infection or reactivation\n* Age \\>1 day\n* Recipients who have had a stem cell transplant must be at least 21 days after stem cell infusion\n* Clinical status must allow tapering of steroids to \\\u003C 0.5mg\u002Fkg prednisone or other steroid equivalent\n* Must be able to receive CTL infusion in Cincinnati\n* Informed consent obtained by PI or sub-investigator either in person or by phone\n\nExclusion Criteria:\n\n* Active acute GVHD grades II-IV\n* Uncontrolled bacterial or fungal infection\n* Uncontrolled relapse of malignancy requiring treatment with chemotherapy\n* Infusion of ATG or alemtuzumab within 2 weeks of VST infusion\n* Biopsy confirmed acute rejection of solid organ transplant OR empiric treatment of suspected but not confirmed acute rejection of solid organ transplant within the last 30 days","ALL","2 Days",{"count":19,"type":20},750,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The purpose of this study is to demonstrate that viral specific T-cells (a type of white blood cell) can be generated from an unrelated donor and given safely to patients with viral infections.",[26,27,28],"Viral Infection","Viral Reactivation","Infection in an Immunocompromised Host",[30,31,32,33,34,35],"Epstein-Barr Virus (EBV)","Adenovirus (ADV)","Cytomegalovirus (CMV)","T-Cells","Donor","BK virus (BKV)","RECRUITING","2025-12-10",{"date":39,"type":40},"2025-12-16","ACTUAL",{"date":42,"type":40},"2015-09-02",{"date":44,"type":20},"2027-12",{"name":46,"class":47},"Children's Hospital Medical Center, Cincinnati","OTHER",4]